Cannabidiol for Epilepsy – 2019 Study
This is the first cannabis-derived medication (Epidiolex) with approval from the US Food and Drug Administration. This Cannabidiol formulation significantly reduces seizures as an adjunct to standard antiepileptic therapies in patients ≥2 years old with DS and LGS and is well tolerated.
Dogs Epilepsy – 2019 Study
Although a significant reduction in seizure frequency was achieved for dogs in the Cannabidiol group, the proportion of responders was similar between groups. Given the correlation between plasma Cannabidiol concentration and seizure frequency, additional research is warranted to determine whether a higher dosage of Cannabidiol would be effective in reducing seizure activity by ≥ 50%.
Cannabidiol Oil Traumatic Brain Injury (TBI) – 2019 Study (Mouse)
Cannabidiol oral treatment restored the behavioural alterations and partially normalized the cortical biochemical changes. In conclusion, our data show some of the brain modifications probably responsible for the behavioural phenotype associated with TBI and suggest the Cannabidiol as a pharmacological tool to improve neurological dysfunctions caused by the trauma.
Cannabis Oil (THC+CBD) use for Inflammatory Bowel Disease – 2019 Study
Adolescent and young adults with IBD used oral CO and many used other cannabis products as well. Users perceived some medical benefit. Care teams should strive for open communication about use until further information on safety and efficacy becomes available.
Medical Cannabis (30% CBD, 1.5% THC) Treatment in Autism – 2019 Research
After six months of treatment 82.4% of patients (155) were in active treatment and 60.0% (93) have been assessed; 28 patients (30.1%) reported a significant improvement, 50 (53.7%) moderate, 6 (6.4%) slight and 8 (8.6%) had no change in their condition. Cannabis in ASD patients appears to be well tolerated, safe and effective option to relieve symptoms associated with ASD.
Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs
This pharmacokinetic and clinical study suggests that 2 mg/kg of Cannabidiol twice daily can help increase comfort and activity in dogs with OA.
Chronic cannabidiol exposure promotes functional impairment in sexual behavior and fertility of male mice – 2018 Study
The Cannabidiol 30 mg/kg a day group showed a 30% reduction in fertility rate and a 23% reduction in the number of litters. Our results indicate that chronic Cannabidiol exposure promotes functional impairment of the reproductive system of male Swiss mice.
A selective review of medical cannabis in cancer pain management – 2017 Review
There is evidence suggesting that medical cannabis reduces chronic or neu-ropathic pain in advanced cancer patients. However, the results of many studies lacked statistical power, in some cases due to limited number of study subjects. Therefore, there is a need for the conduct of further double-blind, placebo-controlled clinical trials with large sample sizes in order to establish the optimal dosage and efficacy of different cannabis-based therapies.
Medical Cannabis: A New Treatment for Wound Pain-Three Cases of Pyoderma Gangrenosum – 2017 Study
We are reporting a prospective case series of three patients with pyoderma gangrenosum that were treated with topical medical cannabis compounded in nongenetically modified organic sunflower oil. Clinically significant analgesia that was associated with reduced opioid utilization was noted in all three cases. Topical medical cannabis has the potential to improve pain management in patients suffering from wounds of all classes.
Cannabidiol as a Potential Treatment for Anxiety Disorders – 2015 Study
Overall, existing preclinical evidence strongly supports the potential of Cannabidiol as a treatment for anxiety disorders. Cannabidiol exhibits a broad range of actions, relevant to multiple symptom domains, including anxiolytic, panicolytic, and anticompulsive actions, as well as a decrease in autonomic arousal, a decrease in conditioned fear expression, enhancement of fear extinction, reconsolidation blockade, and prevention of the long-term anxiogenic effects of stress.
Cannabidiol in Anxiety and Sleep: A Large Case Series – 2019 Study
The final sample consisted of 72 adults presenting with primary concerns of anxiety (n = 47) or poor sleep (n = 25). Anxiety scores decreased within the first month in 57 patients (79.2%) and remained decreased during the study duration. Sleep scores improved within the first month in 48 patients (66.7%) but fluctuated over time. In this chart review, Cannabidiol was well tolerated in all but 3 patients.
Cannabinoids as novel anti-inflammatory drugs
Cannabinoids, the active components of Cannabis sativa, and endogenous cannabinoids mediate their effects through activation of specific cannabinoid receptors known as cannabinoid receptor 1 and 2 (CB1 and CB2).
• The cannabinoid system has been shown both in vivo and in vitro to be involved in regulating the immune system through its immunomodulatory properties.
• Cannabinoids suppress inflammatory response and subsequently attenuate disease symptoms. This property of cannabinoids is mediated through multiple pathways such as induction of apoptosis in activated immune cells, suppression of cytokines and chemokines at inflammatory sites and upregulation of FoxP3+ regulatory T cells.
• Cannabinoids have been tested in several experimental models of autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, colitis and hepatitis and have been shown to protect the host from the pathogenesis through induction of multiple anti-inflammatory pathways.
• Cannabinoids may also be beneficial in certain types of cancers that are triggered by chronic inflammation. In such instances, cannabinoids can either directly inhibit tumor growth or suppress inflammation and tumor angiogenesis.